🌟Cardiology Conference Calendar🌟

ESC Congress is over! What's up next?

👀rb.gy/potkh

Image of the week
rb.gy/potkh
👀LAA thrombus

Peripheral Admin of Norepi

Prospective observational study

From CHEST
👀rb.gy/gvevk

635 patients:
💙20% received for 24+ hrs
💚51% avoided central line
💛5% had extravasation events

Peripheral NE for short term is safe as bridge to CVC or to avoid CVC

FAME-3 Trial: 3-year outcomes
FFR PCI vs CABG for 3V CAD w EF > 30%

In Circulation

💙No diff composite MACE
💚No diff survival
💛No diff CVA
🧡PCI = more MI

👀rb.gy/th0y6

Curves suggest CABG may win at 5- or 10-year readouts

STOP-CA Trial

Atorva for Anthracycline Cardiac Dysfunction

From JAMA

Of patients receiving anthracyclines:
❤️20% develop LV dysfunction at 1 year
🧡20% develop clinical HF at 5 years

At 1 year, statin reduced rate of LV dysfunction

👀rb.gy/yyczy

TOMAHAWK Trial
CA after OOH Arrest WO STE

From JAMA Cardiology JAMA

At 1 year, no difference:
❤️Mortality
🧡MI or HF
💛Neuro outcome

No advantage to early coronary angiogram after OOH cardiac arrest WO STE

👀rb.gy/o8z0z

S-ICD PAS Trial
Post-Approval Study of SC ICD

From JACC Journals

At 5 years, SC-ICD =
❤️92% 1st shock efficacy
🧡98% final shock efficacy
💛6% device related complication
💚1% electrode related complication
💙16% inappropriate shock rate

👀rb.gy/o9rfu

Image of the week
Coronary stent protrusion
From Carlos Bertolín
#cardiotwitter #cardioX #echofirst

EuroCTO

3-yr outcomes of RCT comparing CTO PCI to OMT

In EuroIntervention

PCI associated with:
💙85% success rate
💙Less ischemia-driven revasc
💙No diffeence AMI
💙No difference CV death

👀rb.gy/ej08f

Dual Organ Transplant:
AHA Scientific Statement

In Circulation

From AHA Science Circulation The ISHLT Michelle Kittleson MD PhD Kavita Sharma Meg Fraser, DNP, NP-C Prateeti Khazanie and others

💙PreTRX renal/hepatic eval and impacts
💙Patient selection
💙Post-op mgmt
💙Ethics

👀rb.gy/3t48m

Zilebesiran for HTN

In NEJM

Phase 1 trial of RNA silencer Zilebesiran for HTN.

Zilebesiran blocks angiotensinogen translation.

1 injection resulted in 24 wks of:
⬇️angiotensinogen
⬇️24-hour BP
↔️adverse events

👀rb.gy/3t48m

#Cardiotwitter #CardioX

PANTHER Study

Patient-level meta-analysis of ASA v P2Y12i for stable CAD.

🤎7 RCTs w 24K patients
💜P2Y12i = less bleeding
💛P2Y12i = less clotting

⏭️Think clopidogrel > ASA long term for CAD

👀Summary
rb.gy/c1alf

👀Article
rb.gy/i2wru

Treatment Strategies for Children with Cardiomyopathy

AHA Scientific Statement

In Circulation
rb.gy/9ozph

💜Affects 1 in 100K children
🤎Mostly HCM and DCM
🧡Risk stratify for SCD
💛Emphasize cause-specific therapies

#CardioTwitter #ACCFIT

CRP v LDL as predictor of CV events in patients on statin therapy

In The Lancet
From Dr. Deepak L. Bhatt & others

Data from 3 RCTs: STRENGTH, PROMINENT, REDUCE-IT

CRP is better predictor if ischemic events than LDL among patients on statin therapy

#CardioTwitter #ACCFIT

Minithoracotomy v Sternotomy for MV Repair

In JAMA

↔️Similar durability at 1 year
↔️Similar function at 12 weeks

#cardiotwitter #ACCFIT

CLEAR Outcomes Trial

Bempedoic acid v placebo to prevent ASCVD events.

Primary prevention subgroup.
In JAMA

Bempedoic acid:
⬇️ASCVD events
⬇️LDL 23%
⬇️HsCRP 14%

⭐️PCSK9i and Zetia never studied in primary prevention

Image of the week
Clot in transit

#cardiotwitter #echofirst

CLEAR Trial:
Bempedoic acid v placebo in statin-intolerant patients

ASCVD primary prevention subgroup analysis

In JAMA

Bempedoic acid
❤️NNT 43 to prevent MACE
🧡Decrease LDL by 34 mg/dL
💛Good primary prevention option

👀rb.gy/zicfj

#CardioTwitter

ESC Consensus
Step-By-Step Short Term MCS For Cardiogenic Shock

From European Society of Cardiology Journals European Society of Cardiology

❤️MCS cannulation
🧡Early MCS mgmt (< 24 hrs)
💛Maintenance MCS mgmt ( >24 hrs)
💙MCS weaning
💚MCS complications

👀Article
shorturl.at/akvGY

👀Summary
rb.gy/d17er

AATS 2023 Expert Consensus:
Donor After Circ Death Cardiac Transplant

In AATS
❤️History and ethics
🧡Donor candidacy + pretreatment
💛Procurement + perfusion
💚Outcomes

👀Article
shorturl.at/vAC26

👀Summary
rb.gy/d17er

#CardioTwitter #ACCFIT